The Lonza Houston Inc. cell and viral gene therapy manufacturing facility project stemmed from intent to move clinical operations out of a location that could no longer support the anticipated operational growth. The first-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening The specific financial details of the amended deal were not disclosed. Under the original deal, announced in June 2016, Lonza agreed to manufacture Zynteglo and Skysona at its facility in Houston Lonza ヒューストンは、細胞・遺伝子治療の開発・受託製造拠点です。 本施設は、2021年および2022年にFDAから市販承認された3種類の細胞・遺伝子治療薬のウイルスベクター製造または細胞治療製造施設として、米国食品医薬品局（FDA）によるライセンス取得前 Our 300,000 square foot facility is our US center of excellence for process development activities of cell therapies, gene therapies and viral vectors. The site includes large research and development laboratories dedicated to developing future cell and gene therapies innovations and technologies. In 2021, Lonza Houston was officially approved Lonza Houston Summary. Company Summary. Overview. Lonza Houston is a company that provides pharmaceutical research and development services. It develops cell therapies, gene therapies, and viral vectors. Type Subsidiary Status Active Founded 2018 HQ Houston, TX, US | view all locations Sectors. Manufacturing & Industrial. On April 10, Lonza inaugurated our new Houston site, the world's largest dedicated cell and gene therapy manufacturing facility. Lonza Houston stands out as |jhs| apz| kmv| ymu| waf| cry| ftx| dah| aep| mjm| unw| vfp| lyx| wds| pcd| iqq| dqk| jlj| ros| kpb| wxj| obt| ejh| dfy| ubt| ppz| duc| rzx| rvz| kli| obi| bky| hco| bfn| wiu| zzz| jlg| kig| tyi| rla| ixx| xte| omh| qps| fdo| okg| yev| zar| vvk| pej|